The first innovation, CAR-Mix, utilizes a combination of engineered macrophages and polyclonal T cells. Early findings from an ongoing investigator-initiated trial show a favorable safety profile, with the first patient dosed earlier this year. Researchers designed this multicellular approach to attack tumors that express mesothelin, effectively managing the diverse antigen landscapes often found in solid-tumor microenvironments.
CellOrigin Targets Solid Tumors with New CAR-Mix and TMT Engager Tech
At the 2026 ASCO Annual Meeting, Hangzhou-based CellOrigin unveiled two advanced solid-tumor therapies while securing a strategic partnership with Walvax Biotechnology. The move signals a shift toward in vivo and multi-cell approaches, aiming to bypass the antigen heterogeneity that historically hampers T-cell treatments in aggressive cancers like ovarian and liver carcinoma.
Simultaneously, the company introduced TMT Engager, an LNP-mRNA-based solution that facilitates the formation of tripartite conjugates between T cells, macrophages, and tumor cells. By triggering both innate and adaptive immune responses, this method has shown significant efficacy in preclinical liver and ovarian cancer models. To scale these breakthroughs, CellOrigin has partnered with Walvax Biotechnology. This collaboration focuses on an investigator-initiated trial for hepatocellular carcinoma, combining CellOrigin’s precision CAR design with Walvax’s large-scale manufacturing and regulatory infrastructure to accelerate clinical translation.
Comments (0)
No comments yet. Be the first!